Weinblatt M E, Kaplan H, Germain B F, Merriman R C, Solomon S D, Wall B, Anderson L, Block S, Irby R, Wolfe F
Brigham and Women's Hospital, Boston, MA 02115.
Arthritis Rheum. 1990 Mar;33(3):330-8. doi: 10.1002/art.1780330305.
Weekly treatment with low-dose oral methotrexate (MTX) was compared with daily auranofin (AUR) treatment in a 36-week double-blind, randomized, multicenter study of 281 patients with active, adult-onset rheumatoid arthritis. Both treatment groups showed significant improvement by the usual measures of clinical efficacy. The response with MTX occurred earlier and was consistently greater than that with AUR. An intent-to-treat analysis showed significantly greater improvement (P less than 0.01) with MTX for painful and swollen joint counts and physician and patient global assessments of disease activity. Adverse reactions were reported more frequently in the AUR group, and more AUR-treated patients were withdrawn from the study because of toxicity. MTX was thus more effective and better tolerated than AUR in this study.
在一项针对281例成年起病的活动性类风湿关节炎患者的为期36周的双盲、随机、多中心研究中，对低剂量口服甲氨蝶呤（MTX）每周治疗方案与金诺芬（AUR）每日治疗方案进行了比较。通过常用的临床疗效指标衡量，两个治疗组均显示出显著改善。MTX组的反应出现得更早，且始终大于AUR组。意向性分析表明，MTX在疼痛和肿胀关节计数以及医生和患者对疾病活动的整体评估方面有显著更大的改善（P<0.01）。AUR组报告的不良反应更频繁，更多接受AUR治疗的患者因毒性而退出研究。因此，在本研究中，MTX比AUR更有效且耐受性更好。
